Tarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on Tuesday

Tarsus Pharmaceuticals (NASDAQ:TARS) is anticipated to announce its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $58.80 million for the quarter.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $50.22 on Tuesday. The firm has a 50-day simple moving average of $52.06 and a two-hundred day simple moving average of $41.99. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Analyst Ratings Changes

Several research analysts have commented on TARS shares. Barclays increased their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Monday, January 27th. Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Guggenheim reissued a “buy” rating on shares of Tarsus Pharmaceuticals in a report on Monday, February 10th. Finally, The Goldman Sachs Group increased their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $56.00.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.